한글목차

유전자 침묵 세계 시장 규모는 2024년 28억 6,000만 달러에서 2030년에는 43억 6,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 CAGR 7.48%를 보일 것으로 예측됩니다.

이 시장은 분자생물학의 급속한 발전, 정밀의료에 대한 관심 증가, 유전적 질환을 표적으로 하는 효과적인 치료법에 대한 수요 증가에 힘입어 강력한 성장세를 보이고 있습니다. 특정 유전자의 발현을 억제하거나 억제하는 기술인 유전자 침묵은 암, 바이러스 감염, 신경 질환 등 다양한 질환의 치료법 개발에 중요한 도구가 되고 있습니다.

유전자 기능에 대한 과학적 이해가 깊어지고 연구 활동이 전 세계적으로 확대됨에 따라, 유전자 침묵은 미래의 헬스케어와 신약개발에 있어 혁신적인 역할을 할 것으로 기대되고 있습니다.

시장 성장 촉진요인

헬스케어 산업의 확대와 정밀의료에 대한 수요

주요 시장 이슈

전달 메커니즘의 한계

주요 시장 동향

RNA 기반 치료제에 대한 관심 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 유전자 침묵 시장에 미치는 영향

제5장 세계의 유전자 침묵 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품 및 서비스별(RNAi, CRISPR-Cas9, 안티센스 올리고뉴클레오티드, 기타)
  • 용도별(신경학, 종양학, 감염증, 대사성 질환, 치료제 제조, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 유전자 침묵 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 유전자 침묵 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 유전자 침묵 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 유전자 침묵 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 유전자 침묵 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 유전자 침묵 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Revvity, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• New England Biolabs, Inc.

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Gene Silencing Market was valued at USD 2.86 billion in 2024 and is projected to reach USD 4.36 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.48% during the forecast period.

This market is witnessing strong growth, fueled by rapid advancements in molecular biology, increasing emphasis on precision medicine, and the growing need for effective therapies targeting genetic conditions. Gene silencing-a technique used to suppress or inhibit the expression of specific genes-has become a critical tool in therapeutic development for a broad spectrum of diseases, including cancer, viral infections, and neurological disorders.

As scientific understanding of gene function continues to deepen and research activities expand globally, gene silencing is poised to play a transformative role in the future of healthcare and drug discovery.

Key Market Drivers

Expanding Healthcare Industry and Demand for Precision Medicine

The healthcare sector's transition toward personalized and targeted treatments is a major catalyst for the adoption of gene silencing technologies such as RNA interference (RNAi) and antisense oligonucleotides (ASOs). RNAi, in particular, offers a rapid and effective mechanism for silencing gene expression across various organisms. It operates by breaking down double-stranded RNA into smaller fragments, which then activate enzymes to selectively degrade corresponding messenger RNA (mRNA), ultimately preventing the production of disease-associated proteins.

These technologies enable a high degree of specificity, allowing for the selective suppression of disease-causing genes while sparing healthy tissues-an approach that is especially valuable in areas like oncology, where conventional treatments may be less effective and can cause harmful side effects.

The increasing prevalence of genetic and rare diseases further underscores the need for gene silencing therapies. Disorders such as thalassemia, sickle cell anemia, and glucose-6-phosphate dehydrogenase (G6PD) deficiency-which are often caused by single-gene mutations-represent ideal candidates for gene-targeted approaches. These conditions exhibit substantial molecular and clinical diversity both across and within populations, highlighting the necessity for tailored therapeutic strategies.

Key Market Challenges

Limitations in Delivery Mechanisms

Despite promising developments, the effective delivery of gene silencing agents remains a significant challenge. These molecules must successfully navigate complex biological barriers to reach their intended targets while avoiding degradation by enzymes or clearance by the immune system. Natural defenses-such as nucleases that break down RNA-can compromise the stability and efficacy of these agents before they reach their target cells.

In addition, target-specific delivery remains a critical hurdle. For gene silencing therapies to achieve therapeutic benefit, they must selectively silence disease-related genes without impacting healthy gene expression. However, existing delivery systems often lack the required precision, raising concerns about off-target effects and unintended gene suppression, which can lead to adverse outcomes. This limitation in delivery efficiency and specificity continues to restrict the widespread clinical translation of gene silencing technologies.

Key Market Trends

Rising Interest in RNA-Based Therapeutics

The momentum behind RNA-based therapies-including RNAi and ASOs-continues to grow rapidly. Currently, there are 18 clinically approved RNA-based drugs, including two mRNA vaccines that became globally recognized during the COVID-19 pandemic. These developments have brought RNA-based science into the mainstream, extending its applications from global health emergencies to rare, individualized conditions.

RNAi therapeutics work by degrading specific mRNA molecules, thereby halting the production of disease-causing proteins. ASOs, meanwhile, bind to mRNA sequences to inhibit translation or trigger degradation. These targeted approaches offer precise regulation of gene expression, making them ideal for addressing diseases at the genetic level.

The customizability of RNA-based therapies allows for the treatment of rare and previously untreatable genetic disorders, positioning gene silencing as a cutting-edge solution in modern medicine. Notable approvals such as Patisiran (for hereditary transthyretin-mediated amyloidosis) and Nusinersen (for spinal muscular atrophy) underscore the clinical viability and therapeutic promise of these approaches.

Key Market Players

• Revvity, Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• GenScript Biotech Corporation
• Merck KGaA
• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• New England Biolabs, Inc.

Report Scope

In this report, the Global Gene Silencing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Silencing Market, By Product & Service:

• RNAi
• CRISPR-Cas9
• Antisense Oligonucleotides
• Others

Gene Silencing Market, By Application:

• Neurology
• Oncology
• Infectious Diseases
• Metabolic Diseases
• Therapeutics Manufacturing
• Others

Gene Silencing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Silencing Market.

Available Customizations:

Global Gene Silencing Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Gene Silencing Market

5. Global Gene Silencing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product & Service (RNAi, CRISPR-Cas9, Antisense Oligonucleotides, Others)
  • 5.2.2. By Application (Neurology, Oncology, Infectious Diseases, Metabolic Diseases, Therapeutics Manufacturing, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Gene Silencing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product & Service
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Gene Silencing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product & Service
      • 6.3.1.2.2. By Application
  • 6.3.2. Mexico Gene Silencing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product & Service
      • 6.3.2.2.2. By Application
  • 6.3.3. Canada Gene Silencing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product & Service
      • 6.3.3.2.2. By Application

7. Europe Gene Silencing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product & Service
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Gene Silencing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product & Service
      • 7.3.1.2.2. By Application
  • 7.3.2. Germany Gene Silencing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product & Service
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Gene Silencing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product & Service
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Gene Silencing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product & Service
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Gene Silencing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product & Service
      • 7.3.5.2.2. By Application

8. Asia Pacific Gene Silencing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product & Service
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Gene Silencing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product & Service
      • 8.3.1.2.2. By Application
  • 8.3.2. India Gene Silencing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product & Service
      • 8.3.2.2.2. By Application
  • 8.3.3. South Korea Gene Silencing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product & Service
      • 8.3.3.2.2. By Application
  • 8.3.4. Japan Gene Silencing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product & Service
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Gene Silencing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product & Service
      • 8.3.5.2.2. By Application

9. South America Gene Silencing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product & Service
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Gene Silencing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product & Service
      • 9.3.1.2.2. By Application
  • 9.3.2. Argentina Gene Silencing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product & Service
      • 9.3.2.2.2. By Application
  • 9.3.3. Colombia Gene Silencing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product & Service
      • 9.3.3.2.2. By Application

10. Middle East and Africa Gene Silencing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product & Service
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Gene Silencing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product & Service
      • 10.3.1.2.2. By Application
  • 10.3.2. Saudi Arabia Gene Silencing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product & Service
      • 10.3.2.2.2. By Application
  • 10.3.3. UAE Gene Silencing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product & Service
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Gene Silencing Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Revvity, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Danaher Corporation
• 15.3. Agilent Technologies, Inc.
• 15.4. GenScript Biotech Corporation
• 15.5. Merck KGaA
• 15.6. Thermo Fisher Scientific, Inc.
• 15.7. Illumina, Inc.
• 15.8. Bio-Rad Laboratories, Inc.
• 15.9. Bio-Techne Corporation
• 15.10. New England Biolabs, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer